The company is advancing its pivotal ARTEMIS Phase 3 trial for wet AMD, with patient enrollment exceeding expectations and anticipated topline data readout in Q1 2027. Adverum has a Buy consensus rating from 4 analysts as of January 2026.
Cyborg Score Rationale
Ixo-vec demonstrates substantial efficacy with significant reductions in treatment burden and consistent long-term durability from multi-year trials. However, the company faces clinical-stage risk with Phase 3 data pending in 2027, modest cash position, and pre-commercial status with near-term burn requirements.
Top Insights
LUNA trial demonstrated 88% reduction in treatment burden and 54% injection freedom, indicating potential for best-in-class efficacy
ARTEMIS Phase 3 enrollment ahead of schedule with topline data expected Q1 2027, de-risking commercial timeline
Company secured $10 million private placement from Frazier Life Sciences to support development and manufacturing scale-up
$83 million manufacturing investment in North Carolina facility to establish GMP commercial production capacity for 200+ employees
Named Competitors
Gene Therapy for Retinal Diseases — Clinical-stage gene therapy developer for ocular and CNS diseases
Gene Therapy for Ocular Diseases — Ophthalmology-focused biopharmaceutical company
AAV Gene Therapy Platform — AAV-based gene therapy company with multiple ocular programs
Cell and Gene Therapy — Gene therapy developer using proprietary AAV vectors
Recent Developments
(January 2026) Buy consensus rating from 4 analysts with $10.50 average price target
(Q4 2025) ARTEMIS Phase 3 patient enrollment completed ahead of schedule with 284 patients
(June 2025) $10 million private placement funding secured from Frazier Life Sciences
(2025) LUNA 2-year follow-up data announced; manufacturing facility in Durham, NC under development
Open the full interactive Adverum Biotechnologies, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.